348. Is the Government More Entrepreneurial Than You Think?

Episode Summary

Executive Summary: Mariana Mazzucato argues that governments are not passive market-fixers but central co-creators of innovation, especially in Silicon Valley, green tech, and pharmaceuticals. She says public institutions take early risks, fund breakthrough technologies, and then fail to capture fair returns or credit. Her solution: mission-oriented state investment, better pricing, equity, data governance, and public-private deals that share both risk and reward.

Main Topics: The entrepreneurial state (Priority: 5/5): Mazzucato reframes government as an active investor and co-creator of innovation rather than a bureaucratic obstacle, using Silicon Valley as the prime example of public-sector-led technological development. Marx, capitalism, and technological change (Priority: 3/5): She explains that Marx influenced her not as an anti-capitalist slogan but as a thinker who deeply understood capitalism’s dynamic, innovation-driven nature. Public investment and unfair returns (Priority: 5/5): The episode argues that institutions like DARPA, NASA, NIH, NSF, and ARPA-E funded key breakthroughs but captured little of the upside, while private firms retained the profits. Misleading narratives about value creation (Priority: 4/5): Mazzucato says storytelling shapes economics: society often praises private firms as wealth creators while ignoring the public contribution behind technologies and markets. Pharma, pricing, and shareholder extraction (Priority: 5/5): She criticizes pharmaceutical firms for spending heavily on buybacks and marketing while charging high prices for drugs whose foundational research was publicly funded. Mission-oriented industrial policy and green innovation (Priority: 4/5): She supports government-led missions on climate, health, and space, arguing that ambitious public programs can coordinate long-term innovation better than market-only logic. Data, patents, and public repositories (Priority: 4/5): Mazzucato proposes that citizens’ data and publicly financed digital infrastructure should generate public value through shared access and stronger public control.

Key Arguments: The state is not merely a de-risker or lender of last resort; it often acts as an investor first resort by funding early, high-uncertainty innovation. Silicon Valley’s success depended on public agencies such as DARPA, NASA, NIH, NSF, and ARPA-E, which funded foundational technologies across the innovation chain. The public sector has co-created major technologies including GPS, the internet, touchscreens, and key drug discoveries, yet receives insufficient financial returns. Government failures like Solyndra should be judged as portfolio risk, not proof that public investment is ineffective, especially when paired successes such as Tesla were under-credited. Public support should come with conditions: equity stakes, royalty rights, price controls, reinvestment requirements, or restrictions on rent extraction. Pharmaceutical pricing is especially problematic because taxpayers often pay twice: first through research funding, then through very high medicine prices. Value is routinely misdefined in modern capitalism; many firms claim to create value while actually extracting it through rents, monopoly power, and financial engineering. The U.S. succeeded because it had an ecosystem of patient finance, mission-oriented agencies, procurement, and scale-up mechanisms—not simply low taxes or entrepreneur incentives. Europe has copied the rhetoric of Silicon Valley but not its state-led structure; China, in her view, is learning the better lesson by using state capacity to build green industries. Big data and digital platforms should be governed as public assets because the underlying technology and citizen-generated data are socially produced resources.

Data Points: Marx reading: Capital, Volumes 1, 2, and 3 - Mazzucato says Marx shaped her understanding of capitalism’s dynamic, innovation-driven character. Solyndra loan: $535 million - U.S. Department of Energy guaranteed loan to Solyndra as part of green stimulus. Obama stimulus: close to $800 billion - Fiscal stimulus program after the financial crisis, including green investment. Tesla loan: $465 million - Comparable U.S. government-guaranteed loan to Tesla. Government equity example: 3 million shares - Mazzucato argues the government structured Tesla/Solyndra deals poorly and should have captured upside through equity. Tesla share price change: $9 to $90 per share - Illustrates how a better government equity structure could have offset losses and captured returns. Elon Musk government financing total: $5 billion - Amount spread across Tesla, SpaceX, and SolarCity. NIH spending: more than $30 billion a year - Annual spending on high-risk, radical research. DOE fracking research: more than $130 million - U.S. government investment in extraction techniques that became fracking. Pharma buybacks/dividends: over 100% of net income - Mazzucato says firms like Pfizer and Amgen spend more on financial payouts than on productive R&D. Priority new molecular entities: over 75% financed by NIH - Claim that a large majority of important drugs relied on public funding. Big pharma pricing mechanism: Bayh-Dole Act, 1980s - Allowed publicly funded research to be patented; she says march-in rights should be used more often.

Pivotal Quotes: "The state was involved in almost everything in Silicon Valley, not to exclude the role of the private sector." — Mariana Mazzucato: On the origin of major innovations and the public role in creating the modern tech economy. "Instead of talking about just facilitating and enabling business, it's really about, you know, taking on the lead investor role as an investor first resort." — Mariana Mazzucato: On how government should be understood in innovation policy. "The U.S. government didn't do that." — Mariana Mazzucato: Referring to the missed opportunity to capture upside from public investment in Tesla-like successes.

Implications: Listeners are left with a challenge to rethink government as a strategic investor and to demand fairer returns, pricing, and governance from firms built on public assets. The broader policy implication is a shift from deregulation to mission-driven, value-sharing capitalism.